What is Cue Biopharma Price-to-Operating-Cash-Flow?
As of today (2024-04-28), Cue Biopharma's share price is $1.365.
Cue Biopharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.88. Hence, Cue Biopharma's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Cue Biopharma's Price-to-Operating-Cash-Flow or its related term are showing as below:
Cue Biopharma's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $-0.23.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.88.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 8.30% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 6.80% per year.
During the past 9 years, Cue Biopharma's highest 3-Year average Operating Cash Flow per Share Growth Rate was 8.30% per year. The lowest was -154.10% per year. And the median was -11.30% per year.
Cue Biopharma Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Cue Biopharma's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cue Biopharma Price-to-Operating-Cash-Flow Chart
|
Cue Biopharma Annual Data
|
|
Trend |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
- |
- |
- |
- |
- |
|
Cue Biopharma Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Cue Biopharma's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Cue Biopharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cue Biopharma's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cue Biopharma's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Cue Biopharma's Price-to-Operating-Cash-Flow falls into.
Cue Biopharma Price-to-Operating-Cash-Flow Calculation
Cue Biopharma's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 1.365 | / | -0.875 |
| = | |
Cue Biopharma's Share Price of today is $1.365.
Cue Biopharma's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.88.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Cue Biopharma (Cue Biopharma) Business Description
Traded in Other Exchanges
Address
40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401.
Executives
| Anish Suri |
officer: President and CSO |
40 GUEST STREET, BOSTON MA 02135 |
| Daniel R Passeri |
director, officer: CEO |
40 GUEST STREET, BOSTON MA 02135 |
| Pamela Garzone |
director |
C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135 |
| Patrick Verheyen |
director |
C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135 |
| Peter A Kiener |
director |
40 GUEST STREET, BOSTON MA 02135 |
| Matteo Levisetti |
officer: Chief Medical Officer |
C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135 |
| Frank Morich |
director |
40 GUEST STREET, BOSTON MA 02135 |
| Fletcher Aaron G.l. |
director |
40 GUEST STREET, BOSTON MA 02135 |
| Patricia Nasshorn |
officer: Chief Business Officer |
C/O WOMEN FIRST HEALTHCARE INC, 12220 EL CAMINO REAL, SAN DIEGO CA 92130 |
| Kerri-ann Millar |
officer: CFO |
40 GUEST STREET, BOSTON MA 02135 |
| Kenneth Pienta |
officer: Chief Medical Officer |
C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
| Sandercock Colin |
officer: SVP, General Counsel and Sec |
40 GUEST STREET, BOSTON MA 02135 |
| Tamar D Howson |
director |
|
| Barry J. Simon |
director |
2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007 |
| Frederick W Driscoll |
director |
|
Cue Biopharma (Cue Biopharma) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CUE has been successfully added to your